Clarius Group LLC Reduces Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Clarius Group LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,794 shares of the medical research company’s stock after selling 190 shares during the quarter. Clarius Group LLC’s holdings in Thermo Fisher Scientific were worth $1,390,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock valued at $17,297,426,000 after purchasing an additional 196,864 shares during the period. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the last quarter. Geode Capital Management LLC lifted its position in Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock valued at $4,075,540,000 after buying an additional 197,442 shares during the last quarter. Norges Bank purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $3,149,754,000. Finally, Northern Trust Corp increased its position in shares of Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on TMO. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. UBS Group cut their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $390.17 on Wednesday. The company has a market cap of $147.29 billion, a P/E ratio of 22.88, a PEG ratio of 2.14 and a beta of 0.78. The firm has a fifty day moving average price of $415.31 and a 200 day moving average price of $490.41. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $389.86 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the prior year, the firm posted $5.11 EPS. The business’s quarterly revenue was up .2% compared to the same quarter last year. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.